AIM Rule 17 Schedule 2(g) Update

RNS Number : 5393Q

C4X Discovery Holdings PLC

28 June 2022

 

C4X Discovery Holdings plc

("C4XD", "C4X Discovery" or the "Company")

AIM Rule 17 Schedule 2(g) Update

28 June 2022 - C4X Discovery Holdings plc (AIM: C4XD), a pioneering Drug Discovery company, announces the following information relating to directors' disclosure under Schedule Two, paragraph (g) of the AIM Rules for Companies:

Alex Stevenson, Non-Executive Director of the Company, has been Chief Scientific Officer of 4D Pharma plc since 18 January 2014. On 24 June 2022, 4D Pharma plc was placed into administration.

- Ends -

Contacts

C4X Discovery Holdings
Mo Noonan, Communications	[phone]
Panmure Gordon (UK) Limited (NOMAD and Broker)
Freddy Crossley, Emma Earl (Corporate Finance)	[phone]
Rupert Dearden (Corporate Broking)
C4X Discovery Media - Consilium Strategic Communications
Mary-Jane Elliott, Chris Gardner, Matthew Neal	[phone]
C4X Discovery Holdings

Notes to Editors:

About C4X Discovery

C4X Discovery ("C4XD") is a pioneering Drug Discovery company combining scientific expertise with cutting-edge Drug Discovery technologies to efficiently deliver world leading medicines, which are developed by our partners for the benefit of patients. We have a highly valuable and differentiated approach to Drug Discovery through our enhanced DNA-based target identification and candidate molecule design capabilities, generating small molecule drug candidates across multiple disease areas including inflammation, oncology, neurodegeneration and addictive disorders. Our commercially attractive portfolio ranges from early-stage novel target opportunities to late-stage Drug Discovery programmes ready for out-licensing to partners and we have two commercially partnered programmes with one candidate in clinical development.

We collaborate with leading pharmaceutical and life sciences companies to enrich our expertise and take our assets through pre-clinical and clinical development. Through early-stage revenue-generating licensing deals, we realise returns from our high value pre-clinical assets which are reinvested to maximise the value of our Drug Discovery portfolio.

 

END

 

 

MSCQVLFLLQLZBBZ